Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Balanced, Randomized, Two-treatment, Two -Period, Two -Sequence, Crossover Bioequivalence Study Comparing a Single Oral Dose of Fenofibrate 130 mg Capsules of Ohm Laboratories Inc. USA (a Subsidiary of Ranbaxy Pharmaceutical Inc.) With Antara® 130 mg Capsules (Containing Fenofibrate 130 mg) of Oscient Pharmaceuticals Corporation USA, in Healthy, Adult, Male, Human Subjects Under Fasting Condition.

NCT02306889 is registered in ClinicalTrials.gov with Ranbaxy Laboratories Limited as lead sponsor.

NCT NCT02306889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02306889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Balanced, Randomized, Two-treatment, Two -Period, Two -Sequence, Crossover Bioequivalence Study Comparing a Single Oral Dose of Fenofibrate 130 mg Capsules of Ohm Laboratories Inc. USA (a Subsidiary of Ranbaxy Pharmaceutical Inc.) With Antara® 130 mg Capsules (Containing Fenofibrate 130 mg) of Oscient Pharmaceuticals Corporation USA, in Healthy, Adult, Male, Human Subjects Under Fasting Condition.
Lead sponsor
Ranbaxy Laboratories Limited
Phase
Not applicable
Overall status
Completed
Start date
January 31, 2010
Completion date
April 30, 2010
Enrollment
48 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy